Skip to main content

Table 1 Baseline characteristics of the study subjects

From: Intralymphatic immunotherapy with tyrosine-adsorbed allergens: a double-blind, placebo-controlled trial

  Cohort for testing procedural safety   Cohort for testing treatment efficacy (at 4 months after ILAIT)   Cohort for testing treatment efficacy (at 1 year after ILAIT)  
  All subjects(n = 32) Active group (n = 19) Control group (n = 13) P-value All subjects (n = 30) Active group (n = 17) Control group (n = 13) P-value All subjects (n = 22) Active group (n = 13) Control group (n = 9) P-value
Age, year 34.2 ± 9.5 32.4 ± 11.1 36.9 ± 5.9 0.037 34.9 ± 9.3 33.4 ± 11.2 36.9 ± 5.9 0.079 36.5 ± 9.7 35.2 ± 11.8 38.4 ± 5.7 0.186
No. of Female 19 (59.4) 11 (57.9) 8 (61.5) 0.565 18 (60.0) 9 (52.9) 8 (61.5) 0.410 13 (59.1) 7 (53.8) 6 (66.7) 0.439
Symptom duration, years 14.5 ± 9.5 15.8 ± 8.7 12.8 ± 10.6 0.648 14.2 ± 9.6 15.4 ± 9.0 12.8 ± 10.6 0.674 14.5 ± 10.0 13.6 ± 10.3 15.4 ± 10.3 0.645
Comorbid allergic diseases
 Asthma 19 (59.4) 11 (57.9) 8 (61.5) 0.470 18 (60.0) 10 (58.8) 8 (61.5) 0.508 13 (59.0%) 7 (53.8) 6 (66.7) 0.436
 Urticaria 7 (21.9) 6 (31.6) 1 (7.7) 0.186 6 (20.0) 5 (29.4) 1 (7.7) 0.240 4 (18.2) 4 (30.8) 0 (0.0) 0.184
 Food allergy 6 (18.8) 5 (26.3) 1 (7.7) 0.294 6 (20.0) 5 (29.4) 1 (7.7) 0.240 5 (22.7) 4 (30.8) 1 (11.1) 0.423
 Drug allergy 5 (15.6) 3 (15.8) 2 (15.4) 0.660 5 (16.6) 3 (17.7) 2 (15.4) 0.657 4 (18.1) 3 (23.1) 1 (11.1) 0.652
 Atopic dermatitis 4 (12.5) 2 (10.5) 2 (15.4) 0.542 4 (13.3) 2 (11.8) 2 (15.4) 0.591 3 (13.6) 2 (15.4) 1 (11.1) 0.642
 Family history of allergic diseases 21 (65.6) 11 (57.9) 10 (76.9) 0.283 20 (66.7) 10 (58.8) 10 (76.9) 0.259 15 (68.2) 8 (61.5) 7 (77.8) 0.372
Target allergen
 Dermatophagoides farinae 22 (68.8) 13 (68.4) 9 (69.2) 0.636 20 (66.7) 11 (64.7) 9 (69.2) 0.554 15 (68.2) 8 (61.5) 7 (77.8) 0.372
 D. pteronyssinus 21 (65.6) 13 (68.4) 8 (61.5) 0.487 19 (63.3) 11 (64.7) 8 (61.5) 0.579 14 (63.6) 8 (61.5) 6 (66.7) 0.584
 Cat 19 (59.4) 10 (52.6) 9 (69.2) 0.285 18 (60.0) 9 (52.9) 9 (69.2) 0.301 12 (54.5) 7 (53.8) 5 (55.6) 0.639
 Dog 8 (25.0) 5 (26.3) 3 (23.1) 0.587 7 (23.3) 4 (23.5) 3 (23.1) 0.660 6 (27.3) 3 (23.1) 3 (33.3) 0.477
  1. Data are shown as the means ± standard deviations (SDs) or frequencies (%). ILAIT intralymphatic allergen-specific immunotherapy